Received Oct 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
she is experiencing muscle weakness now; This non-serious case was reported by a consumer via call center representative and described the occurrence of muscle weakness in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced muscle weakness (Verbatim: she is experiencing muscle weakness now). The outcome of the muscle weakness was not resolved. It was unknown if the reporter considered the muscle weakness to be related to Shingrix. It was unknown if the company considered the muscle weakness to be related to Shingrix. Additional Information: GSK Receipt Date: 25-SEP-2025 The patient reported that she received Shingrix vaccine over a year ago. The patient states she was experiencing muscle weakness now.